Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773746 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPTMAPK1TSHRALOX15 | |
| SCHEMBL5772217 | 0.81 | RAB9A (0.49) | ALDH1A1TSHRRAB9AMEN1KMT2A | |
| SCHEMBL5773517 | 0.74 | KDM4E (0.42) | ALDH1A1MAPTMAPK1ALOX15HSD17B10 | |
| SCHEMBL5772064 | 0.72 | PIM1 (0.46) | KMT2AKDM4E | |
| SCHEMBL7248869 | 0.71 | CASP1 (0.34) | ALDH1A1MAPTALOX15POLBHSD17B10 | |
| SCHEMBL5770807 | 0.68 | MAPT (0.46) | ALDH1A1MAPTALOX15POLBHSD17B10 | |
| SCHEMBL5768892 | 0.67 | PDE7B (0.41) | ALDH1A1RAB9AHSD17B10MEN1KMT2A | |
| SCHEMBL12947818 | 0.64 | KMT2A (0.69) | ALDH1A1MAPTMAPK1TSHRPOLB | |
| SCHEMBL279862 | 0.63 | ALDH1A1 (0.51) | ALDH1A1MAPTMAPK1TSHRALOX15 | |
| SCHEMBL5768754 | 0.62 | SERPINE1 (0.38) | ALDH1A1MAPTMAPK1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472241-A4 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS INC (US) | 2005-06-29 | — | — | EP | claimed |
| EP-1472241-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | Galileo Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | claimed |
| US-6653346-B1 | Amtiischemic and antiinflammatory agents | GALILEO PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | claimed |
| WO-2003066618-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | claimed |
| US-7078541-B2 | Benzofuran derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1472241-A4 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS INC (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005027900-A1 | BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1472241-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | Galileo Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040063975-A1 | Benzofuran derivatives | EDISON PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| US-6653346-B1 | Amtiischemic and antiinflammatory agents | GALILEO PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| WO-2003066618-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063975-A1 | Benzofuran derivatives | NDUFAB1, AIFM1, NDUFAF1 | ALDH1A1 404/4885MAPT 278/4885MAPK1 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.